1117 ECP InterVenn
BioCentury & Getty Images

Emerging Company Profile

InterVenn: liquid biopsy diagnostics based on glycoproteins

InterVenn builds on research by scientific founders Bertozzi, Lebrillo to develop glycoproteomic cancer diagnostics

InterVenn, building on research by scientific co-founders Carolyn Bertozzi and Carlito Lebrilla, is applying AI to develop blood-based glycoproteomic cancer diagnostics.

Nov 18, 2020 | 2:06 AM GMT

InterVenn is tapping the glycoproteome for new markers for blood-based cancer diagnostics and using machine learning to accelerate the biomarker discovery process. 

The company announced Monday that it raised a $34 million series B round led by Anzu Partners and

Read the full 934 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers